TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Percheron Therapeutics ( (AU:PER) ) has provided an announcement.
Percheron Therapeutics has released an updated corporate presentation that includes new information on its program HMBD-002 and an overview of its financial position. The presentation aims to inform shareholders and investors about the company’s progress and future plans, potentially impacting its operations and industry positioning.
The most recent analyst rating on (AU:PER) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is a publicly listed biotechnology company that focuses on developing and commercializing novel therapies for oncology and rare diseases. Its lead program, HMBD-002, is a monoclonal antibody targeting the immune checkpoint regulator VISTA, which has completed a phase I clinical trial in patients with advanced cancer.
Average Trading Volume: 2,975,046
Technical Sentiment Signal: Sell
Current Market Cap: A$8.7M
Find detailed analytics on PER stock on TipRanks’ Stock Analysis page.